Three-year outcomes of a phase Ⅱ study of adjuvant chemotherapy with S-1 plus docetaxel for stage Ⅲ gastric cancer after curative D2 gastrectomy
論文
Randomized, Open-Label Phase II Study Comparing Capecitabine- Cisplatin Every 3 Weeks with S-1-Cisplatin Every 5 Weeks in Chemotherapy-Naïve Patients with HER2-Negative Advanced Gastric Cancer: OGSG1105, HERBIS-4A Trial
Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202
高度リンパ節転移を伴う進行胃癌に対する術前カペシタビン+ シスプラチン療法第Ⅱ相臨床試験(OGSG1401)
Phase II study of 5‑fluorouracil–leucovorin plus bevacizumab for chemotherapy‑naïve older or frail patients with metastatic colorectal cancer (OGSG 0802)
First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602
A Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601)
A phase II study of S‑1 therapy for patients with advanced and recurrent esophageal cancer resistant or intolerable to fluorouracil, platinum, and taxane therapy (OGSG 1404)
Three-Year Outcomes of a Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601)
Randomized phase II study of CPT‑11 versus PTX versus each combination chemotherapy with S‑1 for advanced gastric cancer that is refractory to S‑1 or S‑1 plus CDDP: OGSG0701